Home CompaniesSectorsHealth CarePharmaceuticalsHims & Hers Jumps 10% in a Day, but Losses, an FTC Lawsuit and Thin Cash Flow Keep the Model at Hold

Hims & Hers Jumps 10% in a Day, but Losses, an FTC Lawsuit and Thin Cash Flow Keep the Model at Hold

by Chaudhry Kramat Ali
0 comments
Hims & Hers Health stock analysis

Key Takeaways

  • Quality scores 39/100, as the second-quarter gross margin fell to 64% from 76%, the company lost $97.2 million from operations, and debt of $1.55 billion stands against $324.1 million of equity.
  • Growth scores 92/100 on 38.2% second-quarter revenue growth, although US revenue grew 16% and the June Eucalyptus acquisition added about $40 million.
  • Opportunity scores 69/100 on Yahoo’s 11.8% free cash flow yield, but company figures show negative free cash flow in the first half, and on corrected cash flow the score drops to about 14 with the shares at $30.92, in the lower end of their two-year range.

HIMS

Hims & Hers Health, Inc.

$30.92

Market Cap
$7.21B

P/E Ratio
N/A

2-Year Position

$14.52$64.65

Signal
HOLD

Hims & Hers Health, the telehealth company behind the Hims and Hers brands, rose 10.2% on Friday, October 9, to close at $30.92, recovering Thursday’s 5.0% drop. The rally comes in a harder year for the business: second-quarter revenue grew 38%, helped by an acquisition, yet the company swung to a net loss of $86.3 million, its quarterly gross margin fell to 64% from 76%, and the Federal Trade Commission sued it in July. This Hims & Hers Health stock analysis, based on Yahoo Finance data as of October 11, 2026, explains why the scoring model rates the stock a Hold, and why one Yahoo figure makes the score look stronger than it is.

What Is Happening With the Stock Price

At $30.92, Hims & Hers sits in the lower end of its two-year range of $14.52 to $64.65 on weekly closes, about 113% above the low and 52% below the high. On daily closes the high was $68.74, in February 2025. The shares are down 4.8% this year from $32.47 at the end of 2025. Published reports differ on Friday’s move: Investing.com tied it to an October 7 Washington Post report that the administration is preparing to temporarily allow sales of some restricted peptides, a category Hims has said it plans to enter, while Alphastreet described a sector-wide rally with no company-specific news. The peptide plan has not been announced. The stock fell 14.7% on July 29, when the FTC filed its complaint, and 28.2% of the float is sold short, per Yahoo, which can amplify swings either way.

Quality: Is This a Financially Sound Business?

Quality scores 39/100, just below the 40 the model requires before it can issue a Buy. The trailing gross margin is a high 69.5%, but the second quarter alone came in at 64%, down from 76% a year earlier, as sales shifted toward branded weight-loss products and lower-margin international markets. The -12.8% operating margin reflects the second quarter, when the company lost $97.2 million from operations, and the trailing net margin is -5.5%. Management called about $81 million of second-quarter costs non-recurring, including acquisition, restructuring and FTC legal charges; adjusted EBITDA, which excludes them, was $60.3 million.

The balance sheet is the main caveat in this Hims & Hers Health stock analysis. Shareholders’ equity fell to $324.1 million at June 30 from $540.9 million at the end of 2025, while Yahoo puts total debt at $1.55 billion, mostly convertible notes, for a debt-to-equity ratio of 4.77. The company also owes $702.9 million of deferred acquisition payments, $537.4 million of it within a year, which helps explain a current ratio of 0.93 and a quick ratio of 0.82. Cash and short-term investments were $841.0 million. Return on equity is -32.0% and return on assets -2.2%. Cash flow needs care: Yahoo reports trailing free cash flow of $849 million, but the company’s own figures show free cash flow of -$68.2 million in the second quarter and -$15.2 million for the first half, and Yahoo’s quarterly cash flow data add up to only about $62 million over the past four quarters.

Growth: Does This Company Have Real Upside?

Growth scores 92/100, the strongest pillar. Yahoo’s 38.2% revenue growth figure compares the second quarter with the same quarter of 2025: revenue reached $753.2 million, up from $544.8 million. US revenue rose 16% to $621.8 million, while international revenue jumped to $131.4 million from $7.5 million, helped by the June purchase of Eucalyptus, which the chief financial officer said contributed about $40 million. Subscribers rose 19% to nearly 2.9 million. First-quarter revenue had grown about 4%.

The 64.5% compound growth rate Yahoo labels as five-year covers 2022 to 2025, when annual revenue rose from $526.9 million to $2.35 billion. Management raised its 2026 revenue outlook to $3.1 billion to $3.3 billion, with adjusted EBITDA of $275 million to $325 million. An EV/Revenue multiple of 3.07 looks modest for this growth rate, but part of that growth was bought rather than built.

Opportunity: Is Now a Good Time to Enter?

Opportunity scores 69/100, but the score leans on the suspect cash flow figure. With no P/E (trailing EPS is -$0.64) and a negative EV/EBITDA of -778.15, the valuation score rests largely on Yahoo’s 11.8% free cash flow yield, alongside a high price-to-book ratio of 22.26. Using the roughly $62 million of free cash flow in Yahoo’s quarterly data, the yield is about 0.9%. Re-running the model with that figure cuts Opportunity to about 14, Quality to about 31 and the recommendation score from 67 to about 44, which is still a Hold. The lower-end position in the two-year range adds little, because the model only rewards beaten-down prices when Quality is at least 40. The risks are clear: the FTC lawsuit and a related securities class action, margin pressure from weight-loss products, integrating Eucalyptus, and the debt on the balance sheet. The upside case rests on peptides, international growth and management’s 2030 target of at least $6.5 billion of revenue.

Hims & Hers Health Stock Analysis: The Bottom Line

Our Hims & Hers Health stock analysis finds a fast-growing platform whose profits and cash flow have moved the wrong way this year. Quality is 39/100, Growth 92/100 and Opportunity 69/100, for a recommendation score of 67/100 and a Hold signal, because Quality sits just below the level needed for a Buy. With Yahoo’s free cash flow figure corrected, the score falls to about 44, still a Hold. The bull case is 38% revenue growth, nearly 2.9 million subscribers and raised guidance; the bear case is a GAAP net loss, a 12-point fall in quarterly gross margin, $1.55 billion of debt against $324.1 million of equity, and the FTC case. Third-quarter results on November 9 will show whether margins have stabilized. Buy / Hold / Sell reflects StreetBriefs’ quantitative scoring model (Quality, Growth, Opportunity), a data-driven signal for further research, not a personalized recommendation to transact.

Financial Metrics Summary

Metric Value
Price & Valuation
Current Price $30.92
2-Year Low $14.52
2-Year High $64.65
Market Cap $7.21B
EV / Revenue 3.07
Our Scores
Quality Score 39 / 100
Growth Score 92 / 100
Opportunity Score 69 / 100
Profitability
Earnings Per Share -$0.64
Return on Assets -2.2%
Return on Equity -32.0%
Net Profit Margin -5.5%
Gross Margin 69.5%
Operating Margin -12.8%
Growth
Revenue Growth (5Y CAGR) 64.5%
Revenue Growth (TTM) 38.2%
Balance Sheet
Debt-to-Equity 4.77
Current Ratio 0.93
Quick Ratio 0.82
Income & Dividends
Dividend Yield 0.0%
Payout Ratio 0.0%

Data as of October 11, 2026

Our Three-Pillar Assessment

Quality

39/100

Growth

92/100

Opportunity

69/100

HOLD

OVERALL SIGNAL
Buy / Hold / Sell reflects StreetBriefs’ quantitative scoring model (Quality, Growth, Opportunity) – a data-driven signal for further research, not a personalized recommendation to transact.

Quality measures business fundamentals: profitability, cash flow discipline, and balance sheet strength.

Growth captures revenue momentum, gross margin scalability, and the Rule of 40 efficiency test.

Opportunity signals entry timing: current valuation versus history and price position in the 2-year range.

Current price: $30.92 trading 52% below its 2-year high of $64.65 on weekly closes.

Keep researching HIMS

Follow HIMS’s scores in Qubits Finance

The Quality, Growth and Opportunity scores above come from the same model that powers the Qubits Finance screener. Compare HIMS with its peers, keep it on a watchlist, and see when its scores change. There, the model’s Buy, Hold and Sell signals read Positive, Neutral and Caution.

See HIMS in the screener →What Qubits Finance offers

The screener is on the free plan; accounts are approved by a person during the private beta. Research tools and information only: Qubits Finance does not place trades or make personal recommendations. Want a stock we have not covered? Request an analysis.

This analysis is done using financial data from Yahoo Finance.

Disclaimer: This article is written for informational purposes only and does not constitute investment advice. The analysis is based on publicly available financial data and interpretation of company fundamentals.
Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions.

You may also like

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted